Organ Preservation Market was valued at US$ 0.23 Bn. in 2021. The global Organ preservation Market is expected to grow at a CAGR of 6.6 % through the forecast period.Organ preservation Market Overview:
The supply line for organ transplantation is organ preservation. Currently, flushing the liver, pancreas, and kidney with the University of Wisconsin (UW) organ preservation solution and keeping them at hypothermia can successfully maintain the organs for up to two days (0-5 degrees C). The UW solution works effectively because it contains several substances that are cell impermeant (such as lactobionic acid, raffinose, and hydroxyethyl starch), which stop the cells from expanding during cold ischemia storage. The UW solution also contains glutathione and adenosine, which are substances that may encourage the return of normal metabolism during reperfusion by enhancing the organs' antioxidant capacity (glutathione) or by promoting the synthesis of high-energy phosphates (adenosine) after reperfusion.To know about the Research Methodology:-Request Free Sample Report 2021 is considered as a base year to forecast the market from 2022-2029. 2021’s market size is estimated on real numbers and outputs of the key players and major players across the globe. The past five years' trends are considered while forecasting the market through 2029. 2021 is a year of exception and analysis, especially with the impact of lockdown by region. COVID-19 Impact on Organ preservation Market: In just a few weeks, covid went from a local issue to a pandemic. Healthcare systems around the world have been affected by the pandemic, with hospitals being overrun by the growing number of patients. To handle the increasing number of cases, temporary hospitals were also established. The execution of life-saving treatments like organ transplantation has been impacted by the coronavirus disease because it has changed the process of organ donation and recovery. Organ donation and transplantation have been severely disrupted by the spread of COVID-19. There has been a fall in the demand for organ preservation goods as a result of these actions being disrupted and a considerable reduction in donation and transplant activity. In several places, living donor transplants were suspended during the pandemic while only urgent cases could receive transplants from deceased donors. For a huge number of weak individuals on transplant waiting lists, this meant missed opportunities. In addition, the pandemic has reduced the number of potential organ donors who have passed away, overloaded healthcare infrastructure and intensive care unit (ICU) capacity, restricted access to testing for infection in donors and recipients, and complicated travel/transport logistics for organ retrieval teams.
Organ preservation Market Dynamics:
Drivers: An increase in the number of elderly people and consequent incidences of multiple organ failure One of the most frequent causes of death in ICUs is multiple organ failure, which is primarily brought on by sepsis. According to estimates, up to 20% of individuals with sepsis exhibit acute respiratory failure, and 26–50% develop acute renal failure (Source: Society of Critical Care Medicine). Acute renal failure is more common in the elderly due to age-related declines in renal plasma flow and glomerular filtration rate. Diabetes makes people more susceptible to both of these diseases and multiple organ failure. Geriatric patients are more likely to have illnesses including TB and liver cirrhosis, which may necessitate organ transplantation. The Organ Procurement and Transplantation Network asserts that the increase in the number of elderly individuals undergoing organ transplants has a significant impact on the volume of organ transplantation procedures performed. For instance, the number of organ transplants in the over-65 age category increased in the US from 8,691 in 2019 to 8,895 in 2021. According to the UN World Population Ageing Report, there were 728 million individuals in the world who were 65 or older in 2020; this number is likely to reach 1.5 billion by 2050, indicating the possibility of rising demand. Given that this demographic is more susceptible to illnesses that cause organ failure, its rise will be a major factor in the market's growth. Restraints: An expensive organ transplant procedure Organ transplantation requires a lot of resources, including highly compensated doctors and surgeons, pricey transportation, and expensive medications. The whole cost is increased by the fees for inpatient treatment, organ procurement, preservation, post-operative recipient care, and anti-rejection drugs. For evaluation or follow-up appointments arranged at the transplant center for a recommended length of medical care, patients must additionally incur additional expenses for travel, housing, meals, hospital visits, and another medical testing. For patients with little financial resources, these costs immediately compete with spending on needs like food, clothes, and housing, making organ transplant treatments frequently unattainable without outside assistance. Opportunities: increasing investments in healthcare To provide better healthcare services, governments all around the world are concentrating on bolstering their healthcare infrastructures. For instance, the Brihanmumbai Municipal Corporation in India set aside around USD 924 million (INR 7,000 crore), or 15% of its budget for 2022–2023, to improve health services and create 100 health clinics with more than 100 diagnostic tests for preventative and primary treatment in BMC regions. There will be more hospitals that handle more brain-dead people who might make good donors as a result of these infrastructure upgrades. The time involved with donor-recipient cross-matching, subject profiling, genotyping, and other associated diagnostic tests during the pre-transplantation period will also be improved by the growth in testing labs. It is expected that these discoveries would open up new potential for the organ preservation sector. Challenge: The significant gap between the annual need for organs and the number of donated organs Currently, there is a substantial discrepancy between the number of donated organs and the quantity needed. Over 100,000 patients in the US were on the organ waiting list as a whole. By the end of 2021, only 41,354 transplants had been completed. The little number of organs donated each year is mostly the result of inadequate legislative policies, a lack of public knowledge regarding organ donation, and an increasing danger of organ trafficking. Various governments are also putting into practice updated legislation (such as opt-out laws that imply every citizen is an organ donor except under certain exempt circumstances) and campaigns to promote organ donation.Organ preservation Market Segment Analysis:
Based on Type, the kidney market category held the greatest market share in 2021. The main factors impacting the market growth are the rising number of renal failure cases and kidney transplant operations. In the United States, around 37.00 million people have chronic kidney disease, and nearly 726,000 people get end-stage renal disease annually, according to a report released by the NHS in 2019. It is also expected that various awareness campaigns regarding the advantages of kidney transplantation will encourage segment growth. For instance, the NHS started the "Advancing American Kidney Health" Initiative to better the lives of kidney disease patients in the U.S. Heart segment for the heart is expected to grow at highest CAGR of xx% during the forecast period. The category is estimated to grow at a faster rate over the period due to the increasing number of heart transplant operations. Around 3,408 heart transplant surgeries were carried out in 20121, compared to 3,273 in 2017, according to a study released by the Health Resources & Services Administration. In the upcoming years, it's expected that this trend will fuel the segment's development. The process of caring for and preserving a donor lung from the moment it is obtained until it is implanted in the recipient is known as donor lung preservation. The chance of lung injury during storage or at the moment of reperfusion, as well as the function of the lung upon transplantation, may be affected by several variables, including temperature, perfusion volume and pressure, oxygenation, and degree of inflation. Over the past ten years, a large portion of experimental research in lung transplantation has been devoted to improving lung preservation techniques to lessen the effects of ischemia-reperfusion injury on post-transplant lung function.Based on the Application Pharmaceutical: In situ core cooling, organ preservation fluids, and machine perfusion procedures are all examples of organ preservation. Maximizing donor hemodynamics, using improved surgical procurement methods with minimal dissection of vascular structures, cannulating the abdominal aorta for rapid in situ core cooling, removing abdominal organs in bulk while separating graft components on the back table, using cold storage techniques with a hyperkalemic hyperosmolar solution at a temperature of 4° C, and treating the organs with a hyperkalemic hyperosmolar solution has traditionally been the methods used to achieve optimal organ The majority of hospitals keep organs in static cold storage, which is advantageous for younger donors with high-quality organs The limitations of cold storage have likely been surpassed with the advent of extended donor criteria. Although kidneys can be kept alive for up to 72 hours, after 36 to 48 hours of cold ischemia, they rarely function effectively in the recipient. The pancreas should ideally be transplanted within 6 to 12 hours and the heart and lungs between 4 to 6 hours. Organ Transplant: the organs are frequently transplanted immediately or kept for future research. The outcome will be better the sooner the recipient receives the transplanted organ. The organ is either attached to a tiny organ perfusion device that pumps an icy solution (often supplemented with potassium) through the organ while it is being transported or it is preserved in an icy cold solution to help preserve it. The "cold ischemia time" refers to this period while in transit. Less than six hours should pass between organ procurement and transplantation for the heart and lungs. The cold ischemia time can last up to 24 hours for liver transplants, but normally, surgeons strive for much less time. New techniques for organ preservation have developed recently that might be able to enhance the quality of donated organs or determine their viability. Super-rapid recovery was the first method for organ procurement to be developed. The method that is most frequently utilized involves mechanically perfusing the organ at either normothermic (37 °C) or hypothermic (4–10 °C) temperatures. Kidney perfusion at low temperatures is a rather common procedure. For the preservation of the heart, normothermic preservation has been used, in which the heart receives warm oxygenated blood and beats ex vivo. This method was also used on lungs, which prompted the development of donor lung reconditioning facilities in North America.
Organ preservation Market Regional Insights:
North America had the greatest market share in 2021. North America is expected that it will continue to dominate during the period. The main drivers of growth are the increasing acceptance of cutting-edge healthcare technologies, the high prevalence of chronic kidney disease and heart failure, better payment policies, and rising investments in expanding access to healthcare. Additionally, it is expected that an aging population and an increase in organ transplant surgeries will foster regional market growth. The Asia Pacific is expected to have the fastest growth throughout the period Due to rising healthcare costs, increased patient awareness, d a growing demand for organ transplant procedures, due to growing patient awareness, rising healthcare costs, and growing demand for organ transplant treatments. In the years to come, it is also expected that the aging population, increased rates of kidney and heart failure, and rising healthcare costs would all contribute to the market's growth. The objective of the report is to present a comprehensive analysis of the global Organ preservation Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The reports also help in understanding the Organ preservation Market dynamic, and structure by analyzing the market segments and projecting the Organ preservation Market size. Clear representation of competitive analysis of key players by Vehicle type, price, financial position, product portfolio, growth strategies, and regional presence in the Organ Preservation Market make the report investor’s guide.Organ preservation Market Scope: Inquire before buying
Global Organ preservation Market Report Coverage Details Base Year: 2021 Forecast Period: 2022-2029 Historical Data: 2017 to 2021 Market Size in 2021: US$ 0.23 Bn. Forecast Period 2022 to 2029 CAGR: 6.6% Market Size in 2029: US$ 0.36 Bn. Segments Covered: by Type • kidney • Heart • Lung • Live by Application • Pharmaceuticals • Organ transplantation • Specialty Centers • Others Organ preservation Market by Region
• North America • Europe • The Asia Pacific • South America • The Middle East and AfricaOrgan preservation Market Key Players
• Paragonix Technologies • XVIVO Perfusion AB • Dr. Franz Köhler Chemie GmbH (Germany), • Essential Pharmaceuticals, • LLC (US) • Organix Limited (UK) • 21st Century Medicine (USMedicine, Inc. • Shanghai Genext Medical • Bridge to Life Limited • Preservation Solutions • Carnamedica (Poland) • Transplant Biomedicals • Institut Georges Lopez • Global Transplant Solutions • Organ Preservation Vascular Perfusion Frequently Asked Questions: 1] What segments are covered in the Global Organ preservation Market report? Ans. The segments covered in the Global Organ preservation Market report are based on Type and application. 2] Which region is expected to hold the highest share in the Global Organ preservation Market? Ans. The North American region is expected to hold the highest share in the Global Organ preservation Market. 3] What is the market size of the Global Organ preservation Market by 2029? Ans. The market size of the Global Organ preservation Market by 2029 is expected to reach US$ 0.36 Bn. 4] What is the forecast period for the Global Organ preservation Market? Ans. The forecast period for the Global Organ preservation Market is 2022-2029. 5] What was the market size of the Global Organ preservation Market in 2021? Ans. The market size of the Global Organ preservation Market in 2021 was valued at US$ 0.23 Bn.
1. Global Organ preservation Market Size: Research Methodology 2. Global Organ preservation Market Size: Executive Summary 2.1. Market Overview and Definitions 2.1.1. Introduction to Global Organ preservation Market Size 2.2. Summary 2.2.1. Key Findings 2.2.2. Recommendations for Investors 2.2.3. Recommendations for Market Leaders 2.2.4. Recommendations for New Market Entry 3. Global Organ preservation Market Size: Competitive Analysis 3.1. MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2. Consolidation in the Market 3.2.1 M&A by region 3.3. Key Developments by Companies 3.4. Market Drivers 3.5. Market Restraints 3.6. Market Opportunities 3.7. Market Challenges 3.8. Market Dynamics 3.9. PORTERS Five Forces Analysis 3.10. PESTLE 3.11. Regulatory Landscape by region • North America • Europe • The Asia Pacific • The Middle East and Africa • South America 3.12. COVID-19 Impact 4. Global Organ preservation Market Size Segmentation 4.1. Global Organ preservation Market Size, by Type (2021-2029) • Kidney • Heart • Lung • Liver 4.2. Global Organ preservation Market Size, by Application (2021-2029) • Pharmaceuticals • Organ transplantation • Speciality centers • Others 5. North America Organ Preservation Market (2021-2029) 5.1. North America Organ Preservation Market Size, by Type (2021-2029) 5.1.1. Kidney 5.1.2. Heart 5.1.3. Lung 5.1.4. Liver 5.2. North America Organ Preservation Market Size, by Application (2021-2029) 5.2.1. Pharmaceuticals 5.2.2. Organ transplantation 5.2.3. Speciality centers 5.2.4. Others 5.3. North America Semiconductor Memory Market, by Country (2021-2029) • The United States • Canada • Mexico 6. Europe Organ Preservation Market (2021-2029) 6.1. Europe Organ Preservation Market, by Type (2021-2029) 6.2. Europe Organ Preservation Market, by Application (2021-2029) 6.3. Europe Organ Preservation Market, by Country (2021-2029) • The UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 7. Asia Pacific Organ preservation market (2021-2029) 7.1. Asia Pacific Organ Preservation Market, by Type (2021-2029) 7.2. Asia Pacific Organ Preservation Market, by Application (2021-2029) 7.3. Asia Pacific Organ Preservation Market, by Country (2021-2029) • China • India • Japan • South Korea • Australia • ASIAN • Rest Of APAC 8. The Middle East and Africa Organ Preservation Market (2021-2029) 8.1. The Middle East and Africa Organ Preservation Market, by Type (2021-2029) 8.2. The Middle East and Africa Organ Preservation Market, by Application (2021-2029) 8.3. The Middle East and Africa Organ Preservation Market, by Country (2021-2029) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 9. South America Organ Preservation Market (2021-2029) 9.1. South America Organ Preservation Market, by Type (2021-2029) 9.2. South America Organ Preservation Market, by Application (2021-2029) 9.3. South America Organ Preservation Market, by Country (2021-2029) • Brazil • Argentina • Rest Of South America 10. Company Profile: Key players 10.1. Paragonix Technologies 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2. Paragonix Technologies 10.3. XVIVO Perfusion AB 10.4. Dr. Franz Köhler Chemie GmbH (Germany), 10.5. Essential Pharmaceuticals, 10.6. LLC (US) 10.7. Organix Limited (UK) 10.8. 21st Century Medicine (USMedicine, Inc. 10.9. Shanghai Genext Medical 10.10. Bridge to Life Limited 10.11. Preservation Solutions 10.12. Carnamedica (Poland) 10.13. Transplant Biomedicals 10.14. Institut Georges Lopez 10.15. Global Transplant Solutions 10.16. Organ Preservation Vascular Perfusion